NCT00752687

A Study of ABT-072 in Healthy and Hepatitis C Virus Genotype 1-Infected Adults

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 100 (actual)
• Sponsor: Abbott · Industry
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Accepted

Summary

To evaluate the safety, tolerability and pharmacokinetics of ABT-072 in healthy volunteers and its anti-viral activity in HCV infected subjects.

Detailed description

A blinded, randomized, placebo-controlled trial to study the safety, tolerability, antiviral activity and pharmacokinetic profiles of ABT-072 in healthy and HCV genotype-1 infected adults.

Conditions

• Hepatitis C

Interventions

Type	Name	Description
DRUG	ABT-072	Capsule or powder drug substance from the capsule mixed in an alternative vehicle. For additional information refer to Arm Description.
DRUG	placebo	Capsule, or powder drug substance from the capsule mixed in an alternative vehicle. For additional information refer to Arm Description.

Timeline

• Start date: 2008-09-01
• Primary completion: 2009-05-01
• First posted: 2008-09-15
• Last updated: 2010-10-21

Locations

1 site across 1 country: United States